Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | PDE4A | P27815 | 5/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23876967 | 0.94 | ALDH1A1 (0.59) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL18789684 | 0.88 | CA12 (0.62) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL4283101 | 0.85 | SMN1; SMN2 (0.53) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL3470800 | 0.83 | HSD17B2 (0.57) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL14705104 | 0.82 | KMT2A (0.48) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL28033776 | 0.81 | KMT2A (0.56) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL15417529 | 0.80 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL29440131 | 0.80 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL7684319 | 0.79 | MAPT (0.77) | HSD17B2CA12CA1CA2CA7 | |
| SCHEMBL7093941 | 0.79 | ALDH1A1 (0.62) | HSD17B2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICALC., LTD. (JP) | 2026-04-23 | — | — | US | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-RE46792-E1 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-1954684-B1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-04-10 | — | — | US | disclosed |
| US-8637559-B2 | Oxazole compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-09-03 | — | — | US | disclosed |
| EP-1954684-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007058338-A9 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007058338-A2 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216260-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
| US-20140100226-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
| US-20260108497-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE7B, PDE4B, PDE1B | HSD17B2 123/4885CA12 1905/4885CA1 1395/4885 |
| US-20090221586-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
| US-20200078340-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
| US-20220265613-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 81/4885CA12 1721/4885CA1 673/4885 |
| US-20190070151-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | HSD17B2 92/4885CA12 1478/4885CA1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.